AGIO Share Price Performance
US$25.24
-30.44 (-54.67%)
61.2% undervalued intrinsic discount
US$65.00
Fair Value
Price US$25.24
AnalystHighTarget US$65.00
AnalystLowTarget US$37.23
AnalystConsensusTarget US$42.33
Fair ValueUS$57.00
Share Pricen/a
Agios Pharmaceuticals, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 13 Fair Values set on narratives written by author
AGIO Community Narratives
AN
Fair Value US$57 55.7% undervalued intrinsic discount
Precision Therapies Will Serve Aging Populations While Facing Regulatory Delays
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$37 31.8% undervalued intrinsic discount
Mounting Pricing Pressures And Delays Will Depress Future Outlook
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$42.33 40.4% undervalued intrinsic discount
FDA Approval And Global Partnerships Will Yield Mixed Prospects
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
FDA Approval And Global Partnerships Will Yield Mixed Prospects
Key Takeaways New product launches and regulatory milestones are set to expand market reach and generate multiple long-term revenue streams. Strategic international partnerships and innovation in rare disease therapies enhance profitability and create sustained growth opportunities.Read more
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
US$42.33
40.4% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
124.91% p.a.
Profit Margin
16.98%
Future PE
36.56x
Share price in 2028
US$51.46
Precision Therapies Will Serve Aging Populations While Facing Regulatory Delays
Key Takeaways Accelerated global expansion and rapid market adoption are fueled by strong partnerships, clear patient targeting, and proactive payer and clinician engagement. Multiple near-term clinical advancements and pipeline synergies position Agios for transformative revenue growth and margin improvement, surpassing standard industry progress.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$57
55.7% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
124.92% p.a.
Profit Margin
14.17%
Future PE
64.24x
Share price in 2028
US$68.9
Mounting Pricing Pressures And Delays Will Depress Future Outlook
Key Takeaways Increasing payer pressure and regulatory demands threaten Agios' pricing power, revenue growth, and development timelines amid broader drug affordability concerns. Heavy reliance on a single product and concentrated pipeline exposes Agios to outsized risks from competition, clinical setbacks, and potential economic downturns.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$37
31.8% undervalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
76.71% p.a.
Profit Margin
16.25%
Future PE
74.96x
Share price in 2028
US$44.72
Recently Updated Narratives
AN
FDA Approval And Global Partnerships Will Yield Mixed Prospects
Fair Value: US$42.33 40.4% undervalued intrinsic discount
6 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Mounting Pricing Pressures And Delays Will Depress Future Outlook
Fair Value: US$37 31.8% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Precision Therapies Will Serve Aging Populations While Facing Regulatory Delays
Fair Value: US$57 55.7% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Agios Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -6.88
- -659.11%
- -895.86%
- 0%
About AGIO
- Founded
- 2007
- Employees
- 487
- CEO
- WebsiteView website
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it develops tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
